(FM) Inmunología
Departamento académico
Universidad de Salamanca
Salamanca, EspañaPublicaciones en colaboración con investigadores/as de Universidad de Salamanca (11)
2022
-
Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, Núm. 21, pp. 4771-4781
2020
-
Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma
Blood, Vol. 135, Núm. 26, pp. 2375-2387
-
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma
Blood, Vol. 136, Núm. 2, pp. 199-209
2019
-
Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis
Leukemia, Vol. 33, Núm. 5, pp. 1256-1267
2018
-
Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)
Blood cancer journal, Vol. 8, Núm. 12, pp. 117
2016
-
Effect of mTORC1/mTORC2 inhibition on T cell function: Potential role in graft-versus-host disease control
British Journal of Haematology, Vol. 173, Núm. 5, pp. 754-768
-
Targeting of PI3K/AKT/mTOR pathway to inhibit T cell activation and prevent graft-versus-host disease development
Journal of Hematology and Oncology, Vol. 9, Núm. 1
2009
-
Prolonged idiotypic vaccination against follicular lymphoma
Leukemia and Lymphoma, Vol. 50, Núm. 1, pp. 47-53
2006
-
Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma
Journal of the National Cancer Institute, Vol. 98, Núm. 18, pp. 1292-1301
-
Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation
Leukemia and Lymphoma, Vol. 47, Núm. 1, pp. 29-37
2004
-
Imatinib Inhibits Proliferation of Ewing Tumor Cells Mediated by the Stem Cell Factor/KIT Receptor Pathway, and Sensitizes Cells to Vincristine and Doxorubicin-Induced Apoptosis
Clinical Cancer Research, Vol. 10, Núm. 2, pp. 751-761